JNJ Stock Analysis — Johnson & Johnson
Sector: Healthcare
AI Verdict
JNJ trades at 20.7x next year’s earnings with a 52.7% EPS growth forecast, making it cheap for the growth on offer if its patent moat and pipeline deliver, but the high RSI warns the stock is priced for perfection in the near term.
Competitive Moat
Johnson & Johnson owns a portfolio of globally recognized pharmaceutical, medical device, and consumer health brands, many protected by patents and regulatory exclusivity. Its scale, deep R&D pipeline, and entrenched hospital relationships create high switching costs and recurring demand.
Summary
A 52.7% jump in forward EPS is driving a sharp reset in JNJ’s valuation narrative.
Where It Stands
JNJ has returned 54.03% over the past year, trades at 20.7x next year’s earnings (below the healthcare sector median of 22x), and its RSI of 69.9 signals elevated pullback risk.
Key Metrics
- RSI: 69.9 — Near Overbought
- Trailing P/E: 31.5x
- Forward P/E: 20.7x
- PEG Ratio: 0.60
- Earnings Growth: +0.5%
- Market Cap: $654.5B
- 1-Year Return: 54.03%
Analyst Consensus
22 Buy · 9 Hold · 0 Sell (31 analysts) · Target $287.25
Bull Case
With analysts forecasting 52.7% EPS growth and a forward P/E of 20.7x, you’re paying less than the sector median for unusually rapid earnings acceleration.
Bear Case
An RSI of 69.9 means the stock is flirting with overbought territory, so even a modest P/E compression from 20.7x to the sector median 22x could erase recent gains if growth disappoints.
Catalyst to Watch
Watch for quarterly earnings and drug pipeline updates — any miss on that 52.7% EPS growth expectation would likely trigger a sharp rerating.